Verve Therapeutics Q1 2023 Earnings Report
Key Takeaways
Verve Therapeutics reported pipeline progress and financial results for the first quarter of 2023. The company's lead program, VERVE-101, is being evaluated in the heart-1 clinical trial, and two additional programs are expected to advance into the clinic next year. Verve ended the quarter with $508.7 million in cash, which is expected to fund operations into the second half of 2025.
VERVE-101 clinical trial ongoing with initial data expected in the second half of 2023.
VERVE-102 named second PCSK9-targeting program, leveraging novel GalNAc-LNP delivery with clinical trial initiation expected in the first half of 2024.
VERVE-201 targeting ANGPTL3 progressing with clinical trial initiation expected in the second half of 2024.
Well-capitalized with $508.7 million supporting runway into the second half of 2025.
Verve Therapeutics
Verve Therapeutics
Verve Therapeutics Revenue by Segment
Forward Guidance
Verve expects its capital position is sufficient to fund its operations into the second half of 2025 with a current operating plan that includes Phase 1 development of VERVE-101, VERVE-102, and VERVE-201.